Proactive Investors - Run By Investors For Investors

ReNeuron 'greatly encouraged' by US regulator feedback on CTX cell therapy trial

Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE) tells Proactive they've received positive guidance from the US regulator as they prepare to take their CTX cell therapy candidate for stroke victims into final-stage clinical trials.

Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

December 19 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use